{
    "nct_id": "NCT01716897",
    "title": "A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults",
    "status": "COMPLETED",
    "last_update_time": "2013-05-20",
    "description_brief": "This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "E2609 (elenbecestat) \u2014 BACE1 (beta\u2011secretase) inhibitor, small\u2011molecule"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial description tests E2609 formulations (capsule vs tablet, fed/fasted) in healthy subjects to determine bioavailability \u2014 this indicates a pharmacokinetic/formulation study of a therapeutic compound rather than a diagnostic. The drug identifier E2609 corresponds to elenbecestat, which targets amyloid production by inhibiting BACE (beta\u2011secretase), i.e., it acts on Alzheimer\u2019s disease pathology rather than only symptomatic cognition. \ue200cite\ue202turn0search4\ue202turn0search9\ue201",
        "Act: Web search confirmed E2609 is elenbecestat, a BACE1 (beta\u2011secretase) inhibitor developed by Eisai for early Alzheimer\u2019s disease (Phase 1\u20133 program, MISSION\u2011AD). Preclinical and clinical reports show E2609 inhibits BACE1 activity and lowers A\u03b2 biomarkers, consistent with a disease\u2011modifying mechanism. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: Mapping to the provided category definitions \u2014 elenbecestat is a small\u2011molecule enzyme inhibitor that targets Alzheimer\u2019s pathology (amyloid production via BACE1). Therefore it fits the category 'disease\u2011targeted small molecule'. The described crossover bioavailability study (tablet vs capsule; fed/fasted) is a formulation/PK study and contains no placebo arms, so placebo is not applicable here. \ue200cite\ue202turn0search0\ue202turn0search8\ue201",
        "Web search results used: - Eisai press release describing E2609 (elenbecestat) as a BACE inhibitor and MISSION\u2011AD program. \ue200cite\ue202turn0search4\ue201 - Eisai 2012 release and Phase I data for E2609 (proof of mechanism; A\u03b2 reduction). \ue200cite\ue202turn0search9\ue201 - Nonclinical/CTAD abstract showing E2609 (e2609) decreases CSF BACE1 activity in monkeys. \ue200cite\ue202turn0search1\ue201 - Clinical trial listings (Phase 1/3 MISSION AD and PK/drug\u2011drug interaction studies) referencing elenbecestat/E2609. \ue200cite\ue202turn0search3\ue202turn0search0\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational compound E2609 (elenbecestat) is a BACE1 (beta\u2011secretase) inhibitor that reduces production of amyloid\u2011beta (A\u03b2) peptides \u2014 its mechanism directly targets amyloid pathology in AD. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Act: Web searches confirm E2609 = elenbecestat, an orally bioavailable BACE1 inhibitor developed by Eisai (with Biogen collaboration) that lowered A\u03b2 biomarkers in clinical studies and proceeded into Phase II/III programs (MISSION\u2011AD) before later discontinuation for safety/risk\u2011benefit reasons. These sources support classifying the drug target as amyloid production via BACE. \ue200cite\ue202turn0search5\ue202turn0search3\ue202turn0search9\ue201",
        "Reflect: Mapping the mechanism to CADRO, inhibition of BACE1 (which reduces A\u03b2 generation and downstream amyloid pathology) fits squarely into category A) Amyloid beta. Although the described trial is a PK/formulation (bioavailability) study in healthy volunteers, that does not change the drug's biological target \u2014 therefore the correct CADRO classification is A) Amyloid beta. (Web sources used are listed below.) \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Web search results used (summaries): - Eisai/Biogen Phase II/Phase III program and A\u03b2 effects described in company releases (confirming elenbecestat is a BACE inhibitor that reduced amyloid PET/biomarkers). \ue200cite\ue202turn0search1\ue202turn0search5\ue201 - Company announcements about discontinuation/safety review of Phase III MISSION\u2011AD (context on clinical development). \ue200cite\ue202turn0search3\ue201 - Product/research pages describing elenbecestat (E2609) as a BACE1 inhibitor that lowers plasma/CSF A\u03b2. \ue200cite\ue202turn0search4\ue202turn0search9\ue201"
    ]
}